By Editorial Staff
Published August 24, 2026
In an era where the American healthcare system is under intense scrutiny, Pharmacy Benefit Managers (PBMs) find themselves at the epicenter of a national debate regarding affordability, drug pricing, and administrative transparency. As legislative bodies and private sector stakeholders demand greater clarity, CVS Caremark, the PBM division of CVS Health, is positioning itself as an industry leader by pivoting toward a more transparent, data-driven business model.
In a recent commentary, Ed DeVaney, Executive Vice President and President of CVS Caremark, emphasized that the organization’s shift toward transparency is not merely a compliance-driven exercise to satisfy regulators, but a foundational evolution of its client relationships.
The Core Mandate: Why Transparency Now?
The modern PBM industry is facing an unprecedented wave of public and regulatory pressure. Employers, health plans, and patients are increasingly vocal about the “black box” nature of drug pricing, where rebates, spread pricing, and complex formulary structures have historically obscured the true cost of pharmaceuticals.
DeVaney argues that while the urgency from the market is palpable, the transformation at CVS Caremark is proactive rather than reactive. "Transparency isn’t the direction we’re moving toward because regulators demanded it," DeVaney noted. "It’s foundational to our relationships with our clients."
This sentiment reflects a broader industry recognition: to maintain trust and relevance in an evolving healthcare landscape, PBMs must demonstrate clear, measurable value to the entities that fund prescription drug coverage.
A Chronology of the Shift: From Conventional Models to ‘TrueCost’
To understand the current transformation, one must look at the strategic timeline CVS Caremark has followed over the past several years.
2023: The Launch of TrueCost
In 2023, CVS Caremark introduced its “TrueCost” model. This initiative was designed to address the persistent demand for drug-level pricing visibility. Unlike traditional models that rely on high-level estimates or blended averages—which often masked the specific financial impact of individual drugs—TrueCost provided clients with granular data. This allowed plan sponsors to see exactly how much a drug cost, regardless of whether that value was derived from manufacturer rebates or direct discounts.
2025: Scaling the Framework
Throughout 2025, CVS Caremark aggressively expanded the reach of its new pricing architecture. By prioritizing the integration of transparency tools into standard contracts, the company sought to standardize the reporting experience for its diverse book of business.
January 1, 2026: The Milestone
As of the start of 2026, the transition reached a critical mass: 85% of CVS Caremark’s commercial book of business is now utilizing TrueCost features. This shift is characterized by a deliberate departure from “spread pricing”—a practice where the PBM charges the plan sponsor more than it pays the pharmacy—in favor of a more transparent, pass-through model.
Supporting Data and the Mechanics of Change
The efficacy of these changes rests on the move away from obfuscation and toward actionable, data-backed insights. The TrueCost framework functions by providing clients with three specific pillars of information:
- Drug-Level Transparency: By stripping away the complexity of “blended averages,” clients can analyze the actual cost of specific therapeutic classes and individual molecules.
- Point-of-Sale (POS) Rebates: A significant portion of the shift involves the direct passing of manufacturer rebates and discounts to members at the pharmacy counter, rather than retaining them to offset premiums.
- Enhanced Reporting Capabilities: Clients are now provided with tools that allow for real-time tracking of benefit performance, enabling them to see the immediate impact of formulary adjustments and cost-sharing shifts.
According to industry analysts, this level of granular reporting fundamentally changes the power dynamic between the PBM and the plan sponsor. When a corporation or health plan understands exactly how much they are paying for a specific specialty drug versus a generic equivalent, they are better equipped to design plan benefits that incentivize high-value care.
Empowering the Client: The Role of Decision-Making
A recurring theme in the discourse surrounding PBM reform is the "driver’s seat" fallacy. Often, critics of the PBM industry suggest that the PBMs themselves dictate costs. However, DeVaney argues that the client has always held the ultimate authority over plan design.
"Our clients choose how their plan is designed, including how the value we create gets passed to members," DeVaney stated. "They decide whether rebates flow to the point of sale or to lower premiums, how to structure formularies, and how to balance cost-sharing."
The role of the transparent PBM, therefore, is not to make these decisions for the client, but to provide the clarity necessary to make smarter ones. By eliminating the “fog” of complex pricing, TrueCost enables sponsors to make trade-offs that reflect their specific goals, whether that is lowering out-of-pocket costs for members or managing long-term trend growth.
Official Responses and Industry Implications
The competitive landscape for PBM services is heating up. While established giants like CVS Caremark, Express Scripts, and OptumRx navigate the transition, a wave of “new entrant” PBMs has emerged, promising radical transparency and digital-first models.
The Competitive Response
DeVaney acknowledges the entry of these new players, noting that they often make bold promises about transparency that remain to be tested at scale. "We welcome the competition—it validates what we’ve been building," he said. The implication is that the “transparency” standard, once considered a luxury or a niche offering for sophisticated clients, has now become the industry baseline.
Implications for the Future of Healthcare
The industry is currently witnessing a paradigm shift:
- From Spread to Pass-Through: The era of retail spread pricing is rapidly closing. Contracts that prioritize cost-based pharmacy reimbursement are becoming the industry standard.
- The Focus on Net Cost: Success is no longer measured by the size of the rebate a PBM can negotiate, but by the "net cost" of the drug to the plan and the patient.
- Accountability: With enhanced reporting, PBMs are held to higher standards of performance. If a benefit design underperforms, the data now makes the cause visible, forcing both the PBM and the sponsor to iterate and improve.
Looking Ahead: The PBM of the Future
The evolution of CVS Caremark’s business model represents a broader realization within the healthcare sector: trust is a competitive advantage. As the industry moves toward 2027 and beyond, the definition of a "successful" PBM will likely be measured by the depth of its integration with the client’s financial goals and the clarity of its communication with the end member.
By shifting toward a model that emphasizes the pass-through of manufacturer discounts and the elimination of complex pricing spreads, CVS Caremark is attempting to redefine its role from a transactional vendor to a strategic partner.
Whether this transition will satisfy the more aggressive calls for federal regulation remains to be seen. However, the data from the 2026 fiscal year suggests that the market is rapidly adapting to a new, more transparent reality. For employers and health plans, the days of relying on "black box" metrics are numbered. The future of the PBM industry, at least as projected by its largest players, is one where every dollar spent on a prescription is traceable, justifiable, and fully understood by the parties that bear the cost.
As the industry continues to evolve, the challenge for CVS Caremark and its peers will be to maintain this momentum—balancing the need for operational efficiency with the constant, non-negotiable demand for transparency in an increasingly expensive healthcare market.
